Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: Why were patients at major risk excluded?

doi:10.1136/bmj.331.7530.1474-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Luca Puccetti, president (lucpucce@promedgalileo.org)

Promed Galileo Medical Association, Pisa 56011, Italy

EDITOR—One of the strongest risk factors for gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs (NSAIDs) is known to be previous events. Hippisley-Cox et al excluded patients who had already had a diagnosis of an adverse upper gastrointestinal event before the study period.1 This removes patients at high risk from …